Covered recipient · General Payments record
AMANDA M RUBIN
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
General Payments · PY2022–2024
$980.81
- Reported across 27 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $488.69 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| UCB, Inc. | $162.01 | 4 |
| Genentech USA, Inc. | $70.69 | 3 |
| Ceribell, Inc. | $52.18 | 2 |
| Alexion Pharmaceuticals, Inc. | $46.91 | 2 |
| GENZYME CORPORATION | $37.97 | 1 |
| ABBVIE INC. | $33.61 | 1 |
| Acerta Pharma LLC | $27.31 | 1 |
| Alnylam Pharmaceuticals Inc. | $21.19 | 1 |
| ARGENX US, INC. | $20.73 | 1 |
| JAZZ PHARMACEUTICALS INC. | $16.09 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $33.61 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105984303 | CMS |
| Alexion Pharmaceuticals, Inc. | $18.29 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1094030629 | CMS |
| Alexion Pharmaceuticals, Inc. | $28.62 | 05/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1093908832 | CMS |
| Alnylam Pharmaceuticals Inc. | $21.19 | 04/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125850042 | CMS |
| ARGENX US, INC. | $20.73 | 08/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142111779 | CMS |
| AstraZeneca Pharmaceuticals LP | $27.31 | 03/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104590212 | CMS |
| Ceribell, Inc. | $33.46 | 07/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153957237 | CMS |
| Ceribell, Inc. | $18.72 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153954873 | CMS |
| Genentech USA, Inc. | $17.82 | 03/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132974813 | CMS |
| Genentech USA, Inc. | $29.53 | 05/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132974815 | CMS |
| Genentech USA, Inc. | $23.34 | 07/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132974817 | CMS |
| GENZYME CORPORATION | $37.97 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139988257 | CMS |
| JAZZ PHARMACEUTICALS INC. | $16.09 | 04/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150221920 | CMS |
| UCB, Inc. | $22.13 | 01/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143162682 | CMS |
| UCB, Inc. | $20.16 | 03/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143162684 | CMS |
| UCB, Inc. | $99.47 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143162686 | CMS |
| UCB, Inc. | $20.25 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143162688 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.